share_log

Insmed | 10-Q: Q3 2024 Earnings Report

Insmed | 10-Q: Q3 2024 Earnings Report

Insmed | 10-Q：2024財年三季報
美股SEC公告 ·  2024/10/31 19:05

Moomoo AI 已提取核心訊息

Insmed reported strong financial results for Q3 2024, with total revenue increasing 18.2% to $93.4 million compared to $79.1 million in Q3 2023. The growth was driven by ARIKAYCE sales expansion across all regions, with US revenue up 12.9% to $66.9 million, Japan revenue up 30.9% to $21.0 million, and Europe revenue up 45.3% to $5.6 million.Research and development expenses increased to $150.8 million from $109.1 million in Q3 2023, primarily due to higher manufacturing costs and increased headcount. SG&A expenses rose to $118.9 million from $90.6 million, driven by higher personnel costs and commercial readiness activities for brensocatib. The company reported a net loss of $220.5 million compared to $158.9 million in Q3 2023.The company maintained a strong financial position with $461.5 million in cash and cash equivalents plus $1.0 billion in marketable securities as of September 30, 2024. Insmed remains on track to file an NDA for brensocatib in bronchiectasis in Q4 2024 following positive Phase 3 ASPEN trial results. The company also closed screening for the ENCORE study of ARIKAYCE, with topline data expected in Q1 2026.
Insmed reported strong financial results for Q3 2024, with total revenue increasing 18.2% to $93.4 million compared to $79.1 million in Q3 2023. The growth was driven by ARIKAYCE sales expansion across all regions, with US revenue up 12.9% to $66.9 million, Japan revenue up 30.9% to $21.0 million, and Europe revenue up 45.3% to $5.6 million.Research and development expenses increased to $150.8 million from $109.1 million in Q3 2023, primarily due to higher manufacturing costs and increased headcount. SG&A expenses rose to $118.9 million from $90.6 million, driven by higher personnel costs and commercial readiness activities for brensocatib. The company reported a net loss of $220.5 million compared to $158.9 million in Q3 2023.The company maintained a strong financial position with $461.5 million in cash and cash equivalents plus $1.0 billion in marketable securities as of September 30, 2024. Insmed remains on track to file an NDA for brensocatib in bronchiectasis in Q4 2024 following positive Phase 3 ASPEN trial results. The company also closed screening for the ENCORE study of ARIKAYCE, with topline data expected in Q1 2026.
Insmed在2024年第三季度報告了強勁的財務業績，總營業收入同比增長18.2%，達到9340萬美金，相較於2023年第三季度的7910萬美金。增長主要受到ARIKAYCE在所有地區銷售擴展的推動，美國營業收入增長12.9%，達到6690萬美金，日本營業收入增長30.9%，達到2100萬美金，歐洲營業收入增長45.3%，達到560萬美金。研究和開發費用從2023年第三季度的10910萬美金增加到15080萬美金，主要是由於製造業成本的增加和員工人數的增加。SG&A費用從9060萬美金上升至11890萬美金，主要由於人員成本和brensocatib的商業準備活動增加。公司報告淨虧損爲22050...展開全部
Insmed在2024年第三季度報告了強勁的財務業績，總營業收入同比增長18.2%，達到9340萬美金，相較於2023年第三季度的7910萬美金。增長主要受到ARIKAYCE在所有地區銷售擴展的推動，美國營業收入增長12.9%，達到6690萬美金，日本營業收入增長30.9%，達到2100萬美金，歐洲營業收入增長45.3%，達到560萬美金。研究和開發費用從2023年第三季度的10910萬美金增加到15080萬美金，主要是由於製造業成本的增加和員工人數的增加。SG&A費用從9060萬美金上升至11890萬美金，主要由於人員成本和brensocatib的商業準備活動增加。公司報告淨虧損爲22050萬美金，相較於2023年第三季度的15890萬美金。截至2024年9月30日，公司保持了強大的財務狀況，現金及現金等價物爲46150萬美金，加上10億美金的可交易證券。Insmed仍按計劃在2024年第四季度提交brensocatib在支氣管擴張症的NDA，因其積極的Aspen三期試驗結果。公司還關閉了對ARIKAYCE的ENCORE研究的篩選，預計將在2026年第一季度公佈頂線數據。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間